• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19: Management
CMECNE

COVID-19 Guidance: Key Highlights for Healthcare Professionals

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Describe reporting and testing for the novel 2019 coronavirus
2. Discuss CDC guidelines for prevention of transmission of the novel 2019 coronavirus

Estimated time to complete activity: 0.5 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from 03-23-2020 through 03-23-2022, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Read Disclaimer & Fine Print

NOTE: Information and guidelines may change rapidly. Check in with listed references in ‘Learn More – Primary Sources’ to best keep up to date. This summary has been updated with the latest CDC guidelines on when to end quarantine.

SUMMARY:

The novel coronavirus, named SARS-CoV-2, is the pathogen underlying the pandemic (a global outbreak of disease). The disease associated with this virus has been officially named COVID-19. Coronaviruses represent a large family of viruses. They can cause human illness, but many are found in animals and, rarely, animal coronaviruses can evolve and infect people as was the case in previous infectious outbreaks such as MERS and SARS.


  • COVID-19 Definitions
  • Symptoms
  • Those at Risk
  • Travel Warnings
  • Recommendations for Reporting, Testing, and Specimen Collection
  • Healthcare Personnel: Infection Prevention
  • Discontinuation of Transmission-Based Precautions
  • Hospital Discharge
  • Quarantine

COVID-19 Definitions

  • Mild Illness: Individuals who have
    • Any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnea, or abnormal chest imaging
  • Moderate Illness: Individuals who have
    • Evidence of lower respiratory disease by clinical assessment or imaging and
    • Saturation of oxygen (SpO2) ≥94% on room air at sea level
  • Severe Illness: Individuals who have
    • Respiratory frequency >30 breaths per minute
    • SpO2 <94% on room air at sea level (or, for patients with chronic hypoxemia, a decrease from baseline of >3%)
    • Ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mmHg
    • Lung infiltrates >50%
  • Critical Illness: Individuals who have
    • Respiratory failure
    • Septic shock
    • Multiple organ dysfunction

Symptoms

  • Incubation period
    • Time from exposure to development of symptoms: 2 to 14 days
    • 97.5% of persons with COVID-19 who develop symptoms will do so within 11.5 days of SARS-CoV-2 infection (see ‘Related ObG Topics’ below)
    • Median time from exposure to symptoms onset: 4-5 days
  • Signs and Symptoms
    • Fever or chills
    • Cough
    • Shortness of breath or difficulty breathing
    • Fatigue
    • Muscle or body aches
    • Headache
    • New loss of taste or smell
    • Sore throat
    • Congestion or runny nose
    • Nausea or vomiting
    • Diarrhea
  • Additional points regarding presentation
    • Older adults: Especially those with comorbidities may have delayed presentation of fever and respiratory symptoms
    • Fatigue, headache, and muscle aches (myalgia) are among the most commonly reported symptoms in people who are not hospitalized
    • Sore throat and nasal congestion or runny nose (rhinorrhea) also may be prominent symptoms
    • GI symptoms may be relatively common
      • Nausea, vomiting or diarrhea may occur prior to fever and lower respiratory tract signs and symptoms
    • Loss of smell (anosmia) or taste (ageusia) has been commonly reported, especially among women and younger or middle-aged patients

Those at Risk Based on Evidence (CDC)

  • Age
    • The CDC states

Age is the strongest risk factor for severe COVID-19 outcomes. Approximately 54.1 million people aged 65 years or older reside in the United States; in 2020 this age group accounted for 81% of U.S. COVID-19 related deaths, and as of September 2021 the mortality rate in this group was more than 80 times the rate of those aged 18-29

Comorbidities with ≥1 meta-analysis or systematic review or by review method defined in Scientific Evidence brief

  • Cancer
  • Cerebrovascular disease
  • Chronic kidney disease*
  • Chronic lung diseases limited to:
    • Interstitial lung disease
    • Pulmonary embolism
    • Pulmonary hypertension
    • Bronchopulmonary dysplasia
    • Bronchiectasis
    • COPD (chronic obstructive pulmonary disease)
  • Chronic liver diseases limited to:
    • Cirrhosis
    • Non-alcoholic fatty liver disease
    • Alcoholic liver disease
    • Autoimmune hepatitis
  • Diabetes mellitus, type 1 and type 2*
  • Heart conditions (such as heart failure, coronary artery disease, or cardiomyopathies)
  • Mental health disorders limited to:
    • Mood disorders, including depression
    • Schizophrenia spectrum disorders
  • Obesity (BMI ≥30 kg/m2)*
  • Pregnancy and recent pregnancy
  • Smoking, current and former
  • Tuberculosis

Comorbidities with ≥1 observational study (e.g., cohort, case-control, or cross-sectional)

  • Children with certain underlying conditions
  • Down syndrome
  • HIV (human immunodeficiency virus)
  • Neurologic conditions, including dementia
  • Overweight (BMI ≥25 kg/m2, but <30 kg/m2)
  • Sickle cell disease
  • Solid organ or blood stem cell transplantation
  • Substance use disorders
  • Use of corticosteroids or other immunosuppressive medications

Comorbidities with mostly case series, case reports, or, if other study design, the sample size is small 

  • Cystic fibrosis
  • Thalassemia

Comorbidities that are supported by mixed evidence (association in at least one meta-analysis or systematic review and additional studies or reviews that reached different conclusions about risk associated with a medical condition)

  • Asthma
  • Hypertension, possibly*
  • Immune deficiencies (except people with moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments)

Footnote:

* indicates underlying conditions for which there is evidence for pregnant and non-pregnant people

Travel Warnings

  • Updated travelers’ warnings can be found within the CDC Novel Coronavirus Summary page below (‘Learn More – Primary Sources’)

KEY POINTS:

Recommendations for Reporting, Testing, and Specimen Collection

Diagnostic Testing – Specimen Collection

  • Obtain an upper respiratory specimen for initial diagnostic testing
    • A nasopharyngeal (NP) specimen collected by a healthcare professional or
    • An oropharyngeal (OP) specimen collected by a healthcare professional or
    • A nasal mid-turbinate swab collected by a healthcare professional or by a supervised onsite self-collection (using a flocked tapered swab) or
    • An anterior nares (nasal swab) specimen collected by a healthcare professional or by onsite or home self-collection (using a flocked or spun polyester swab) or
    • Nasopharyngeal wash/aspirate or nasal wash/aspirate (NW) specimen collected by a healthcare professional
  • Lower respiratory tract specimens
    • Collect and test sputum in patients who develop a productive cough | Induction of sputum is not recommended
    • Under certain clinical circumstances (e.g., those receiving invasive mechanical ventilation), a lower respiratory tract aspirate or bronchoalveolar lavage sample should be collected and tested as a lower respiratory tract specimen

Note: CDC does not recommend using antibody testing to diagnose acute infection | Use a viral (nucleic acid or antigen) test to diagnose acute infection

Healthcare Personnel: Infection Prevention

  • Healthcare personnel: CDC advises use of
    • Gloves
    • Gowns
    • Airborne precautions
    • Eye protection (e.g., goggles or a face shield)
  • Face masks are an acceptable alternative when the supply chain of N95 respirators (or similar respirators that filter inspired air and offer respiratory protection) cannot meet the demand
  • If respirators are in short supply, priority should be given to aerosol-generating procedures
  • CDC addresses alternatives in the setting of face mask shortages on the page entitled Strategies for Optimizing the Supply of Facemasks (see ‘Learn More – Primary Sources’)

Discontinuation of Isolation Following a Positive Test

Symptom-Based

  • Isolation may be discontinued if
    • ≥5 days since symptoms first appeared and
    • ≥24 hours have passed since last fever without the use of fever-reducing medications and
    • Symptoms (e.g., cough, shortness of breath) have improved
    • Continue to wear a mask around others for an additional 5 days

Note: Patients who are severely immunocompromised may produce replication-competent virus beyond 20 days after symptom onset or, for those who were asymptomatic throughout their infection, the date of their first positive viral test | Consultation with infectious diseases specialists is recommended | Use of a test-based strategy for determining when Transmission-Based Precautions may be discontinued could be considered

Hospital Discharge

  • Patient can be discharged from hospital with COVID-19 when clinically indicated even if not having met criteria for discontinuation of Transmission-Based Precautions
  • If not yet met criteria for discontinuation of Transmission-Based Precautions
    • Decision should be made with clinical care team and local or state public health departments
    • Take in to consideration patient’s home situation and whether it is appropriate for home isolation recommendations (e.g., separate bedroom, appropriate caregivers, access to PPE, potential risk to others in the home who may be at risk)

Quarantine

  • The purpose of quarantine is to separate someone who might have been exposed to COVID-19 with the goal of preventing transmission to others

Unvaccinated or Incomplete Vaccination  

  • (1) Unvaccinated or (2) >6 months from Second mRNA Dose and not Boosted or (3) >2 Months after the J&J Vaccine and not Boosted
    • Quarantine for 5 days
    • Strict mask use for an additional 5 days

Note: If 5-day quarantine is not feasible, always wear a well-fitting mask when around others for 10 days

Vaccinated with Complete Primary Series (with Booster if Appropriate)

  • (1) Completed Primary mRNA Vaccine Series Within Last 6 Months or (2) Completed Primary J&J Vaccine Within Last 2 Months or (3) Have Received Booster
    • Quarantine following an exposure is not required
    • Wear a mask for 10 days after the exposure.
    • Best practice: Test for SARS-CoV-2 at day 5 after exposure

Note: If symptoms occur, quarantine immediately until a negative test confirms symptoms are not attributable to COVID-19

Learn More – Primary Sources:

Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Providers

CDC Coronavirus Disease 2019: Overview of Testing for SARS-CoV-2

CDC: Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)

CDC: Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-19 in Healthcare Settings (Interim Guidance)

CDC Coronavirus Disease 2019: Guidelines for Clinical Specimens

CDC: Interim U.S. Guidance for Risk Assessment and Work Restrictions for Healthcare Personnel with Potential Exposure to COVID-19

CDC: Coronavirus Disease 2019 Information for Travel

Clinical Questions about COVID-19: Questions and Answers

CDC: Strategies for Optimizing the Supply of Facemasks

Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic

CDC: Implementing Home Care

CDC: Quarantine and Isolation

WHO: Novel coronavirus Information Page

JAMA: Coronavirus Disease 2019

FDA: Coronavirus Disease 2019

BMJ: Coronavirus Updates

Lancet: Coronavirus Hub

NEJM: 2019 Novel Coronavirus

Annals of Internal Medicine: Content Related to Coronavirus in Annals of Internal Medicine

CDC: Standard Precautions

CDC: Contact and Airborne Precautions

CDC: Middle East Respiratory Syndrome (MERS)

CDC: Severe acute respiratory syndrome (SARS)

JAMA: What Is a Pandemic?

Take a post-test and get CME credits

TAKE THE POST TEST

Get Guideline Notifications direct to your phone with ObGFirst®

Try It Free »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19: Management Posts
Next >

Related ObG Topics:

Coronavirus and Pregnancy: CDC Guidance and Professional Recommendations
ARDS, Critical Care and COVID-19: ‘Surviving Sepsis Campaign’ Guidelines and Key Points
COVID-19 and NSAIDs: Is There Reason for Concern with Use of Ibuprofen?
COVID-19: The Importance of GI Symptoms and Elevated LFTs
Further Evidence for a 5 Day COVID-19 Incubation Period
Loss of Taste and Smell: Key Symptoms of COVID-19 Infection
NIH COVID-19 Treatment Guidelines

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site